Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

About this update from Ovid Therapeutics Inc.

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the Company will host a KCC2 Deep Dive R&D event highlighting its first-in-class KCC2 portfolio on Tuesday, April 14, 2026, at 9:30 am ET in New York, NY, which will also be webcast simultaneously. During the event independent expert clinicians and translational experts as well as Ovid’s President and Chief Executive Officer Meg Alexander, will discuss the Company’s proprietary portfolio of potential first-in-class direct activators of KCC2, including pharmacodynamic data, translational and clinical development strategy, and the potential market opportunity. Ovid is developing a portfolio of unique molecules, which include OV350 (an intravenous tool program and KCC2 direct activator), OV4071 (an oral KCC2 direct activator) and next-generation development candidates that have differentiated potential therapeutic profiles and formulations. These direct activators have the potential to become broad franchises of medicines for neurological and neuropsychiatric conditions including various psychoses, epilepsies, and neurodevelopmental and neurodegenerative disorders. The event will also feature remarks from multiple leading neuroscientists, including: Michael Halassa, M.D., Ph.D., Professor, Patient Research Center, Fralin Biomedical Research Institute at VTC, Department of Psychiatry and Behavioral Medicine, Virginia Tech Carilion School of Medicine, Department of Biomedical Engineering, College of Engineering, Virginia TechOliver Howes, M.B.B.S., Ph.D., Head of Department, Psychosis Studies, Professor of Molecular Psychiatry at the Institute of Psychiatry, Psychology & Neuroscience, King's College LondonEliseo Oeste Salinas, M.D., M.s.C., Senior R&D Advisor to Ovid and veteran drug developer Webcast Information Ovid will host a live webcast of the event at 9:30 am ET on Tuesday, April 14, 2026. The live webcast of the event can be accessed through the Events & Presentations section of Ovid’s website. Participants may register for the webcast here and are advised to do so at least 10 minutes prior to joining the event. A replay of the webcast will be archived on Ovid’s website for 90 days following the event. About Ovid Therapeutics Ovid Therapeutics...

View stock analysis, news, and events for Ovid Therapeutics Inc.